Wall Street still sees an upside for rare disease drug development as FDA looks to fill knowledge gaps
It’s full steam ahead for rare disease drug development as both the FDA and Wall St. analysts signaled increasing interest of late.
The FDA on Friday sought to further propel the burgeoning space with a new request for comment under its Accelerating Rare disease Cures Program, and SVB Securities analysts said in a note on today that rare disease drugs remain “attractive” to investors.
With an aim to accelerate the availability of safe and effective treatments for rare diseases, the FDA says it wants to better understand and address knowledge gaps in the development process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
